Cargando…

Dalfampridine for Mobility Limitations in People With Multiple Sclerosis May Be Augmented by Physical Therapy: A Non-randomized Two-Group Proof-of-Concept Pilot Study

Purpose: To demonstrate proof-of-concept for a combined physical therapy and pharmacological intervention and obtain preliminary estimates of the therapeutic efficacy of a motor-relearning physical therapy intervention with and without concurrent dalfampridine treatment on gait speed in people with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Plummer, Prudence, Markovic-Plese, Silva, Giesser, Barbara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Rehabilitation Sciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9397954/ https://www.ncbi.nlm.nih.gov/pubmed/36188834 http://dx.doi.org/10.3389/fresc.2021.795306

Ejemplares similares

Brief composite mobility index predicts post-stroke fallers after hospital discharge
por: Plummer, Prudence, et al.
Publicado: (2022)

Study on Dalfampridine in the treatment of Multiple Sclerosis Mobility Disability: A meta-analysis
por: Shi, Jianzhen, et al.
Publicado: (2019)

Sensory training system for use at home by people with complex regional pain syndrome in England: protocol for a proof-of-concept study
por: Coggins, Jessica, et al.
Publicado: (2023)

Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis
por: Hayes, Keith C
Publicado: (2011)

Dalfampridine: Review of its Efficacy in Improving Gait in Patients with Multiple Sclerosis
por: Sahraian, M.A., et al.
Publicado: (2011)

A Massive Overdose of Dalfampridine
por: Fil, Laura J., et al.
Publicado: (2015)

Clarification of Dalfampridine Labeled Indications
por: Rabinowicz, Adrian L., et al.
Publicado: (2012)

Dalfampridine sustained-release for symptomatic improvement of walking speed in patients with multiple sclerosis
por: Jeffery, Douglas R, et al.
Publicado: (2010)

Oral Dalfampridine Improves Standing Balance Detected at Static Posturography in Multiple Sclerosis
por: Prosperini, Luca, et al.
Publicado: (2014)

Dalfampridine in the treatment of multiple sclerosis: a meta-analysis of randomised controlled trials
por: Zhang, Enyao, et al.
Publicado: (2021)

Dalfampridine effects on cognition, fatigue, and dexterity
por: Korsen, Melanie, et al.
Publicado: (2016)

Can wrist-worn devices and a smartphone application influence arm activity in children with unilateral cerebral palsy? A proof-of-concept study
por: Turner, Amie, et al.
Publicado: (2023)

Patient-centred rehabilitation for non-communicable disease in a low-resource setting: study protocol for a feasibility and proof-of-concept randomised clinical trial
por: Heine, Martin, et al.
Publicado: (2019)

Study protocol for Vitality: a proof-of-concept randomised controlled trial of exercise training or complex mental and social activities to promote cognition in adults with chronic stroke
por: Best, John R, et al.
Publicado: (2018)

Effects of priming intermittent theta burst stimulation on upper limb motor recovery after stroke: study protocol for a proof-of-concept randomised controlled trial
por: Zhang, Jack Jiaqi, et al.
Publicado: (2020)

IL-11 in multiple sclerosis
por: Zhang, Xin, et al.
Publicado: (2015)

An Adjustable Magnetic Levator Prosthesis for Customizable Eyelid Re-Animation in Severe Blepharoptosis: Design and Proof-of-Concept
por: Kurukuti, Nish Mohith, et al.
Publicado: (2023)

Inclusion in limited distribution drug network reduces time to dalfampridine access in patients with multiple sclerosis at a health-system specialty pharmacy
por: Peter, Megan E, et al.
Publicado: (2021)

Regulation of Suppressors of Cytokine Signaling as a Therapeutic Approach in Autoimmune Diseases, with an Emphasis on Multiple Sclerosis
por: Ramgolam, Vinod S., et al.
Publicado: (2011)

Video game therapy on mobility and dual tasking in multiple sclerosis: study protocol for a randomised controlled trial
por: Baroni, Andrea, et al.
Publicado: (2021)

Development of a behavioural intervention for cognitive fatigability in multiple sclerosis: Protocol for a pilot and feasibility study
por: Walker, Lisa A. S., et al.
Publicado: (2022)

Identification of metabolites of dalfampridine (4-aminopyridine) in dog and rat
por: Caggiano, Anthony, et al.
Publicado: (2013)

Objective and subjective measures of dalfampridine efficacy in clinical practice
por: Klineova, Sylvia, et al.
Publicado: (2018)

Dalfampridine Prior Authorization Program: A Cohort Study
por: Gleason, Patrick P., et al.
Publicado: (2013)

Patient Perspectives and Experience with Dalfampridine Treatment in Multiple Sclerosis-Related Walking Impairment: The Step Together Program
por: Crayton, Heidi, et al.
Publicado: (2014)

Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States
por: Jara, Michele, et al.
Publicado: (2015)

Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system
por: Xiong, Rui, et al.
Publicado: (2023)

Automated recognition of functioning, activity and participation in COVID-19 from electronic patient records by natural language processing: a proof- of- concept
por: Meskers, Carel G. M., et al.
Publicado: (2022)

Protocol for rapid onset of mobilisation in patients with traumatic spinal cord injury (PROMPT-SCI) study: a single-arm proof-of-concept trial of early in-bed leg cycling following acute traumatic spinal cord injury
por: Mac-Thiong, Jean-Marc, et al.
Publicado: (2021)

Augmented reality-guided periacetabular osteotomy—proof of concept
por: Kiarostami, Pascal, et al.
Publicado: (2020)

Using mobile health to encourage physical activity in individuals with intellectual disability: a pilot mixed methods feasibility study
por: Michalsen, Henriette, et al.
Publicado: (2023)

Spinal Mobility Limitation Can Be the Main Reason of Kinesiophobia in Ankylosing Spondylitis
por: Sari, Ilker Fatih, et al.
Publicado: (2023)

Activated IL-1RI Signaling Pathway Induces Th17 Cell Differentiation via Interferon Regulatory Factor 4 Signaling in Patients with Relapsing-Remitting Multiple Sclerosis
por: Sha, Yonggang, et al.
Publicado: (2016)

Prescriber utilization of dalfampridine extended release tablets in multiple sclerosis: a retrospective pharmacy and medical claims analysis
por: Jara, Michele, et al.
Publicado: (2014)

The effectiveness of amantadine and dalfampridine in improving fatigue in patients with multiple sclerosis: A randomized, double-blind, clinical trial
por: Sadeqi, Yasaman, et al.
Publicado: (2022)

Conditions and strategies influencing sustainability of a community-based exercise program incorporating a healthcare-community partnership for people with balance and mobility limitations in Canada: A collective case study of the Together in Movement and Exercise (TIME™) program
por: Aravind, Gayatri, et al.
Publicado: (2023)

Correlates of Objectively Measured Physical Activity Among People With Multiple Sclerosis: A Cross-Sectional Study
por: Fortune, Jennifer, et al.
Publicado: (2021)

Validity and Acceptability of Wearable Devices for Monitoring Step-Count and Activity Minutes Among People With Multiple Sclerosis
por: Lavelle, Grace, et al.
Publicado: (2022)

Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients
por: Limone, Brendan L, et al.
Publicado: (2013)

Increasing Patient Safety Among Multiple Sclerosis (MS) Drug Dalfampridine Users by Expanding Awareness of the Serious Side Effects
por: Zaman, Rameez, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dr4u7t5hm2s30anp9ut79llikq